article thumbnail

Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23 [Drug Discovery and Translational Medicine]

ASPET

Mirikizumab effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12. In both local and systemic in vivo mouse models, mirikizumab blocked IL-23-induced keratin mRNA or IL-17 production, respectively.

article thumbnail

The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers [Drug Discovery and Translational Medicine]

ASPET

In cell-based assays, pegozafermin had a similar receptor engagement profile as native FGF21, with approximately 8-fold higher potency at FGF receptor 1 (FGFR1).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO

Covalent Modifiers

Herein, we used a targeted covalent inhibition strategy and identified a covalent inhibitor, TD19, which selectively inhibits ALKBH5 compared with FTO demethylase in protein-based and tumor cell-based assays. TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA.

RNA 63
article thumbnail

Expanding Your Assay Specificity: Cisbio Joins PerkinElmer

PerkinElmer

The structure of HTRF reagents also makes assays highly resistant to most experimental conditions, and particularly well suited for cell-based assays.

article thumbnail

Genetic variant identification: unveiling the power of STING-seq

Drug Target Review

The perennial challenge with STING-seq (and all cell-based assays) is finding the right cell type for the disease or trait. This encompasses many common diseases and we are optimistic that STING-seq will be a useful platform to rapidly understand which variants and genes are key players in these diseases.

article thumbnail

Atherosclerotic vascular disease | BMG LABTECH

BMG Labtech

In this blog, we highlight some of the solutions available for researchers to tackle atherosclerotic vascular disease: from fundamental research rooted in ischemia-reperfusion studies and cell-based assays to drug discovery efforts and the early detection of drug-related side effects. What is atherosclerotic vascular disease?

Disease 52
article thumbnail

ChEMBL 34 is out!

The ChEMBL-og

University of Dundee: T. 1813 bioactivities in total have been added.